Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481273 · ClinicalTrials.gov registry record
AVIDA The Vidaza® (Azacitidine) Patient Registry
A clinical trial, sponsored by Celgene.
- Completed
- Registry status
- 479
- Enrollment target
NCT00481273 is a clinical trial that has completed, run by Celgene. The registered enrollment target is 479 participants.
The verdict
NCT00481273 has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- 479 participants
- Enrollment target
Study Summary
This registry is a prospective, multi-center, observational study compiling data on the natural history and management of patients receiving Vidaza, and will provide unique insights into the management of myelodysplastic syndromes (MDS) and other hematological disorders and the impact of these disorders on patients.
Interventions
- DRUG Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2006-10-31 |
| Est. Completion | 2010-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00481273
The ClinicalTrials.gov registry entry for NCT00481273 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 479 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azacitidine is the first listed.
NCT00481273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00481273 about?
NCT00481273 is a clinical study titled "AVIDA The Vidaza® (Azacitidine) Patient Registry". This registry is a prospective, multi-center, observational study compiling data on the natural history and management of patients receiving Vidaza, and will provide unique insights into the management of myelodysplastic syndromes (MDS) and other hematological disorders and the impact of these disor...
What is the current status of trial NCT00481273?
This trial is currently completed. The enrollment target is 479 participants. The study started on 2006-10-31. Estimated completion is 2010-08-31.
What interventions are being tested in trial NCT00481273?
The interventions under investigation include: Azacitidine (DRUG).
Who is sponsoring clinical trial NCT00481273?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.